便秘药物纳地美定的作用功效和特殊人群用药详述

Introduction: Naldemedine is a drug used to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It blocks the constipating effects of opioids by binding to opioid receptors in the intestines without affecting the analgesic effects of opioids because it does not cross the blood-brain barrier. This article mainly talks about the effects and efficacy of naldimedine, medication for special groups, drug interactions, safety and tolerability, etc.

Effects

1. Treatment and prevention of constipation: Nadimedine is a new type of constipation treatment drug. It was launched in Japan in 2017 and has been approved for sale in many countries. It not only treats constipation but also prevents it. This is mainly achieved by its action on the intestines, stimulating the movement of the large intestine and promoting defecation. Unlike traditional laxatives, naldimedine does not change the structure and species of intestinal flora, thus helping to maintain intestinal health.

2. Improve intestinal peristalsis: Naldimedine can stimulate mu receptors on the intestinal wall, thereby increasing intestinal contractility and peristalsis. This helps stool pass smoothly through the digestive system, preventing constipation and promoting normal bowel function.

3. Reduce symptoms of constipation: Nadimedine can effectively help relieve symptoms of constipation, such as difficulty defecation, bloating and discomfort. By promoting intestinal emptying, stool passes through the intestines more easily, thereby relieving the patient's pain.

Drug use in special groups

1. Elderly patients: Elderly patients usually have higher drug sensitivity and possible risks of side effects. Elderly patients should follow routine dosage and medication guidelines when receiving naldimedine.

2. Patients with hepatic and renal insufficiency: For patients with hepatic and renal insufficiency, naldimedine should be used with caution. Because the metabolism and excretion of naldimedine may be affected by hepatic and renal function, these patients may require dose adjustments or additional treatments. It is recommended to conduct liver and kidney function evaluation before use and make adjustments according to the doctor's recommendations.

3. Pregnant and lactating women: Pregnant and lactating women should be particularly careful when using Nadimetine. There is a lack of safety and efficacy data on the use of naldimedine in pregnant and lactating women.

4. Children: Nadimedine has not been fully studied and evaluated in children. Nadimedine is not recommended for use in pediatric patients.

Drug interactions

When using naldimedine, the doctor should be informed of other drugs being used to avoid possible drug interactions. In particular, interactions with opioids may affect the efficacy and safety of naldimedine.

Safety and Tolerability

It has been proven to have good safety and tolerability through clinical trials. Its bioavailability is low. After being metabolized and decomposed by intestinal flora, it is eventually excreted as inactive metabolites and is almost not absorbed into the bloodstream. The drug's effects are limited to the intestines and has no toxic or side effects on other organs in the body.

Naldimedine has demonstrated significant therapeutic effects in the treatment of constipation, especially in improving intestinal motility, reducing constipation symptoms, improving quality of life, and reducing constipation caused by opioids. The use of naldimedine in special groups should be carefully evaluated and selected based on the patient's specific situation and the doctor's recommendations.